Skip to content

Merck Is in Advanced Talks to Acquire Biotech Firm Seagen

  • Transaction could value Seagen at $37 billion or more
  • Merck aiming to announce deal ahead of earnings this month
Merck & Co. headquarters in Kenilworth, New Jersey.

Merck & Co. headquarters in Kenilworth, New Jersey.

Photographer: Christopher Occhicone/Bloomberg

Merck & Co. is in advanced talks to acquire Seagen Inc. and could reach an agreement as soon as this month, people familiar with the matter said. 

An offer price of at least $200 per share is under discussion, one of the people said. That would represent a roughly 14% premium to Seagen’s last closing price and translate into a valuation of $37 billion or more, data compiled by Bloomberg show.